Who makes Rivotril®?

Rivotril® is developed by Centro de Atencion e Investigacion Medica.

What development phase is Rivotril® in?

Rivotril® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Rivotril®

Centro de Atencion e Investigacion Medica · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Rivotril®
Sponsor	Centro de Atencion e Investigacion Medica
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study of Clonazepam 2 Mg Tablets (PHASE4)
Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome (NA)
Excessive Crying in Children With Cerebral Palsy and Communication Deficits (PHASE4)
Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rivotril® CI brief — competitive landscape report
Rivotril® updates RSS · CI watch RSS
Centro de Atencion e Investigacion Medica portfolio CI